Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair

ClinicalTrials.gov ID: NCT07226791

Public ClinicalTrials.gov record NCT07226791. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 6, 2026, 9:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Double-Blind, Placebo-Controlled, Adaptive, Dose-Escalation Study to Evaluate the Safety and Efficacy of AGN-151607-DP (USAN: gemibotulinumtoxinA) for the Achievement of Primary Fascial Closure Without the Use of Component Separation Technique, in Subjects Undergoing Open Abdominal Ventral Hernia Repair

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A ventral hernia happens when the muscles in the front of your belly become weak and let organs push through, causing a bulge. If it gets worse, intestines can slip into the bulge, leading to serious pain and health problems. This study aims to asses if AGN-151607-DP is safe and effective for closing the belly wall after open ventral hernia surgery, without needing a complex procedure. Adverse Events and change in disease activity will be assessed. AGN-151607-DP is an investigational drug being developed to treat ventral hernia. Participants will be randomly placed in treatment groups to receive either AGN151607-DP or matching placebo. Approximately 200 adult participants with midline ventral hernia needing open surgical repair will be enrolled in approximately 30 sites in the United States. Participants will receive intramuscular injections of AGN-161607-DP or matching placebo on Day 1. Duration of the study is approximately 25 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular weekly visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Study identification

NCT ID
NCT07226791
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
AbbVie
Industry
Enrollment
200 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 3, 2026
Primary completion
Aug 31, 2028
Completion
Apr 30, 2030
Last update posted
Aug 24, 2026

2026 – 2030

United States locations

U.S. sites
13
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
CARI Clinical Trials INC /ID# 278844 Riverside California 92504 Recruiting
University of Florida - Jacksonville /ID# 261992 Jacksonville Florida 32209 Completed
Medical Research Center /ID# 278680 Miami Florida 33144 Recruiting
Avanza Medical Research Center /ID# 278885 Pensacola Florida 32503 Recruiting
NorthShore University-Endeavor Health Evanston Hospital /ID# 277995 Evanston Illinois 60201 Recruiting
Integrity Clinical Research /ID# 278710 Wichita Kansas 67202 Completed
Mayo Clinic Hospital Rochester /ID# 278995 Rochester Minnesota 55905 Recruiting
Novant Health New Hanover Regional Medical Center /ID# 261979 Wilmington North Carolina 28401-7407 Recruiting
Cleveland Clinic - Cleveland /ID# 277914 Cleveland Ohio 44195 Recruiting
Penn State Milton S. Hershey Medical Center /ID# 261987 Hershey Pennsylvania 17033-2360 Recruiting
Prisma Health Greenville Memorial Hospital /ID# 261995 Greenville South Carolina 29605-4210 Recruiting
Baylor University Medical Center /ID# 261955 Dallas Texas 75246 Recruiting
Carilion Roanoke Memorial Hospital /ID# 278577 Roanoke Virginia 24014 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07226791, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 24, 2026 · Synced Sep 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07226791 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →